Lilly to launch multi-dose weight-loss drug device in US
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
BofA on Eli Lilly (LLY): 'Novo’s GLP-1 price update unlikely to ‘rock the boat’'
February 24, 2026 10:11 AM ESTBofA Securities analyst Tim Anderson reiterated a Buy rating and $1,293.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Todays announcement that Novo Nordisk (covered by Sachin Jain) plans to slash GLP-1 list prices offers a flashy headline, but in our view the update is unlikely to have any material impact on the US market. The price announcement is relevant only to commercial insurance channel (est. 30% of 25... More
Novo To Cut Ozempic, Wegovy's US List Prices By Up To 50% - WSJ
February 24, 2026 7:41 AM ESTNovo To Cut Ozempic, Wegovy's US List Prices By Up To 50% - WSJ
"Under the changes, both Ozempic and Wegovy will list for $675 a month, effective Jan. 1, 2027. That is half of the current price tag for anti-obesity therapy Wegovy and a 34% cut for diabetes treatment Ozempic. The... More